 Anlotinib AL3818 is a kind of innovative medicines approved by State Food and Drug AdministrationSFDA:2011L00661 which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR1VEGFR2VEGFR3FGFR123PDGFRaβ c-Kit and MET. 